List of Excipients in Branded Drug BENTYL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	BENTYL	dicyclomine hydrochloride	50090-4553	SODIUM CHLORIDE
A-S Medication Solutions	BENTYL	dicyclomine hydrochloride	50090-4553	WATER
Allergan Inc	BENTYL	dicyclomine hydrochloride	58914-080	SODIUM CHLORIDE

Last updated: September 7, 2026

BENTYL, the brand name for dicyclomine hydrochloride, is a mature anticholinergic treatment for functional bowel disorders, especially irritable bowel syndrome. Its commercial opportunity is not based on exclusivity for the active ingredient. The stronger opportunities are differentiated oral delivery, palatable liquids, lower-pill-burden products, preservative-free parenteral supply, and formulations designed around tolerability and adherence.

BENTYL Excipient Strategy and Commercial Opportunities for Dicyclomine Hydrochloride

What is BENTYL and how is it used?

BENTYL contains dicyclomine hydrochloride, an anticholinergic and antispasmodic agent indicated for the treatment of patients with functional bowel or irritable bowel syndrome symptoms. The product has historically been supplied in oral capsules, tablets, oral solution and intramuscular injection forms, although current availability varies by market and manufacturer. [1]

Dicyclomine reduces gastrointestinal smooth-muscle spasm through anticholinergic activity. Its commercial limitations include dry mouth, blurred vision, dizziness, constipation, urinary retention and other anticholinergic effects. The FDA label contraindicates use in infants younger than six months, breastfeeding women and patients with certain obstructive or severe gastrointestinal conditions. [1]

The excipient strategy therefore must address four commercial requirements:

1. Reliable dose delivery at relatively low active-ingredient loading.
2. Acceptable taste and mouthfeel for liquid products.
3. Robust stability for a hygroscopic or moisture-sensitive oral solid product.
4. Safe administration in a population that may include older adults with polypharmacy and increased sensitivity to anticholinergic effects.

What dosage forms and excipients are used in BENTYL products?

The historical BENTYL dosage forms use conventional pharmaceutical excipients. Exact compositions can differ among the brand, authorized generic and ANDA products. The FDA-approved label and current DailyMed records should control any formulation comparison. [1,2]

Dosage form	Typical strength	Commercial role	Key excipient considerations
Oral capsule	10 mg	Flexible low-dose oral administration	Gelatin shell, colorants, filler selection, moisture control and powder-flow performance
Oral tablet	20 mg	Higher-strength solid dose	Compressibility, disintegration, hardness, friability and swallowability
Oral solution	Common historical presentation	Patients unable to swallow tablets or capsules	Taste masking, preservative system, pH, microbial control and dose-measuring accuracy
Intramuscular injection	20 mg/2 mL	Acute or short-term use when oral administration is unsuitable	Sterility, endotoxin control, container compatibility and preservative strategy

Historical product labels identify conventional excipients such as lactose, corn starch, talc, povidone and magnesium stearate in solid oral presentations. The specific excipient profile is product-dependent and should not be assumed to apply to every dicyclomine product. [1,2]

The active dose is small relative to the total tablet or capsule mass. That creates an important formulation issue: content uniformity depends heavily on blending, particle-size control, segregation prevention and validated sampling. A direct-compression formulation may be commercially attractive, but wet granulation or dry granulation may provide better control if the active ingredient has poor flow or poor compressibility.

Which excipients are most suitable for a new BENTYL oral solid?

A conventional immediate-release tablet is the lowest-risk development path. It can use widely accepted excipients with established regulatory precedent in immediate-release oral dosage forms.

Fillers and diluents

Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate and pregelatinized starch are potential fillers. Selection should reflect the target market and the intended product claim.

• Lactose can support low-cost conventional tablets but is unsuitable for patients with severe lactose intolerance and may create a labeling issue for some buyers.
• Microcrystalline cellulose supports direct compression and tablet robustness.
• Mannitol can improve mouthfeel and is useful in orally disintegrating tablets.
• Dibasic calcium phosphate can improve flow and hardness but may increase tablet density and affect disintegration.
• Pregelatinized starch can provide both binding and disintegration functionality.

For a differentiated product, a lactose-free formulation has a clearer commercial message than a routine change in filler. The benefit is strongest when paired with a clean-label, low-dose or geriatric-adherence positioning.

Binders and granulation aids

Povidone, copovidone, hydroxypropyl cellulose and pregelatinized starch can control granule strength and tablet integrity. Excessive binder levels can slow dissolution and create hard tablets that are difficult for older patients to swallow.

A development program should establish a narrow operating range for binder concentration, granulation endpoint and drying conditions. The principal risk is not chemical instability alone. It is dose nonuniformity caused by poor distribution of the low-dose active ingredient.

Disintegrants

Croscarmellose sodium, crospovidone and sodium starch glycolate are established choices for immediate-release tablets. Crospovidone is attractive where rapid water uptake and low gel formation are desired. Croscarmellose sodium can provide strong disintegration at low concentrations but must be evaluated against lubricant level and compression force.

A fast-disintegrating 20 mg tablet could improve usability without requiring a novel active ingredient. That product would compete on convenience rather than clinical superiority.

Lubricants and glidants

Magnesium stearate is widely used but can slow wetting and dissolution when over-lubrication occurs. Sodium stearyl fumarate may offer an alternative in formulations where dissolution or magnesium-related labeling concerns matter. Colloidal silicon dioxide can improve powder flow, but excessive amounts can alter blend behavior and tablet ejection.

The commercial goal should be a robust manufacturing process rather than a long excipient list. A formulation with fewer excipients can reduce supplier qualification, analytical testing and change-control burden.

What excipients are best for a dicyclomine oral solution?

An oral liquid is the most commercially differentiated dosage form because it addresses swallowing difficulty and permits flexible dosing. Its main development problem is taste. Dicyclomine's anticholinergic and salt characteristics can produce a bitter or medicinal profile that may require multiple taste-masking mechanisms.

Sweeteners and bulk agents

Sucrose, sorbitol, glycerin, maltitol and xylitol are possible sweetening or bulking agents. The choice affects:

• Caloric content.
• Dental labeling.
• Gastrointestinal tolerance.
• Osmolality.
• Viscosity.
• Microbial risk.
• Suitability for diabetic patients.

Sorbitol and xylitol can cause gastrointestinal discomfort at sufficient doses. That is a meaningful issue for a product intended for patients with gastrointestinal symptoms. A lower-polyol formulation may have a better tolerability profile than a highly sweetened liquid.

Flavor systems

Cherry, berry, citrus and vanilla profiles can mask bitterness, but flavor effectiveness depends on pH, sweetener type, viscosity and the concentration of dicyclomine hydrochloride. Flavor selection should be tested in the final formulation, not in a placebo vehicle alone.

Cyclodextrins, ion-exchange resins, coated drug particles and lipid-based taste-masking systems may improve palatability. These approaches add manufacturing and control complexity. A resin-based system can also affect drug release, dose uniformity and assay recovery.

Preservatives

Methylparaben, propylparaben, benzoic acid, sodium benzoate and potassium sorbate are possible antimicrobial systems, subject to pH and formulation compatibility. Preservative efficacy must be demonstrated in the finished product under USP requirements. [3]

A preservative-free multidose oral solution is difficult to justify unless the container and dosing system materially reduce contamination risk. Unit-dose packaging may be a stronger commercial option for institutional use, emergency kits or travel products.

pH and buffering

The formulation should balance chemical stability, taste, preservative efficacy and container compatibility. A citrate or phosphate buffer may be appropriate, but the final pH must be selected using stability and dissolution data rather than taste testing alone.

A low-pH solution may improve preservative performance but increase taste intensity and potentially affect patient acceptance. A near-neutral formulation may be more palatable but harder to preserve.

What commercial opportunities exist for BENTYL excipient innovation?

The strongest opportunities are differentiated generic or 505(b)(2)-type products rather than attempts to extend the basic BENTYL tablet.

1. Lactose-free immediate-release tablets

A lactose-free 20 mg tablet could target patients who avoid lactose and pharmacies seeking a simple substitution for conventional products. This is a modest opportunity because multiple generic dicyclomine tablets already exist.

2. Orally disintegrating tablets

An orally disintegrating tablet could reduce swallowing difficulty and create a new product profile. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose and flavor systems are common development tools.

The main risks are taste exposure in the mouth, friability, moisture sensitivity and packaging cost. A blister package with strong moisture protection may be required. The product would need comparative bioavailability or other regulatory support appropriate to its legal pathway.

3. Taste-masked oral solution

A well-designed oral solution is more differentiated than another tablet. The product could target older adults, patients with dysphagia and caregivers administering medication through oral syringes.

Commercial success would depend on measured improvements in palatability, dosing accuracy and packaging. A calibrated oral syringe, unit-dose cup or bottle adapter may have greater practical value than a marginal flavor improvement.

4. Unit-dose and institutional packaging

Hospitals, long-term-care facilities and specialty pharmacies may value unit-dose packaging, tamper evidence and clear administration instructions. The formulation itself may remain conventional, while the commercial product is differentiated by packaging, supply reliability and medication-administration workflow.

5. Preservative-free injection supply

Dicyclomine injection has a narrower market but may have supply value where injectable antispasmodics are needed. The manufacturing barrier is substantial because sterile production, container closure, particulate control and stability requirements raise cost.

A preservative-free single-dose ampule or vial could have an institutional niche. It would not automatically create durable pricing power because injectable generic competition is typically price-sensitive.

6. Combination or symptom-directed products

A combination with another gastrointestinal active ingredient could create regulatory and safety complexity. Dicyclomine already has anticholinergic adverse effects, so combinations with agents that increase constipation, urinary retention, sedation or cognitive burden may face a weak commercial rationale.

A symptom-directed product with a clear clinical positioning would require evidence beyond excipient optimization. Excipient changes alone cannot support a new efficacy claim.

How strong is the BENTYL patent estate?

BENTYL has a weak exclusivity position because dicyclomine is an old active ingredient and generic products are commercially established. The principal competitive barriers are manufacturing quality, distribution, supply reliability and regulatory execution.

Exclusivity category	BENTYL assessment
New chemical entity exclusivity	Expired
Basic active-ingredient patent	Expired or commercially irrelevant
Formulation patent leverage	Limited for conventional products
Orange Book patent barrier	No material current barrier identified for routine dicyclomine substitution
Generic competition	Established
Biosimilar risk	Not applicable; dicyclamine is a small-molecule drug
Manufacturing barrier	Low for tablets; moderate for liquids; high for sterile injection
Differentiation potential	Moderate for oral liquids, ODTs and packaging

The FDA Orange Book remains the controlling source for current approved products, listed patents, pediatric exclusivity and regulatory exclusivity. [4] No biosimilar pathway applies because BENTYL contains a chemically synthesized small molecule, not a biologic.

When does BENTYL lose exclusivity and what is the generic entry risk?

BENTYL's original regulatory and patent exclusivity expired decades ago. Generic entry is therefore not a future event. It is the existing market structure.

For a new dicyclomine product, the relevant risk is substitution by established ANDA products. A conventional tablet with the same strength and route will face price competition, pharmacy substitution and limited ability to maintain premium pricing.

A differentiated product can reduce direct substitution if it has:

• A distinct dosage form.
• A meaningful patient-use advantage.
• A proprietary taste-masking system.
• A protected device or package.
• Reliable supply in a shortage-prone presentation.
• A regulatory pathway that supports product-specific labeling.

Paragraph IV litigation is unlikely to create meaningful value for a routine new dicyclomine formulation unless the product relies on a live formulation or method-of-use patent. Any patent strategy would need to focus on a genuinely novel delivery system, composition or manufacturing process rather than the active ingredient.

What regulatory pathway applies to a new dicyclomine product?

A conventional tablet or capsule may qualify for an abbreviated new drug application if it meets the applicable reference-product, strength, dosage-form, route and bioequivalence requirements. A materially different oral solution, ODT or delivery system may require a more complex regulatory analysis.

Potential pathways include:

• ANDA for a therapeutically equivalent generic product.
• 505(b)(2) application for a product relying partly on FDA findings for dicyclomine but containing meaningful differences in formulation, dosage form or route.
• New NDA pathway if the sponsor makes substantial new clinical claims or develops a new combination.

The regulatory strategy should be selected before excipient optimization. A formulation that is commercially differentiated may also require additional clinical, pharmacokinetic, safety or human-factors work.

What patent and IP strategies can protect a new BENTYL formulation?

The most credible IP targets are narrow and technical:

1. Composition claims covering a specific taste-masked dicyclomine system.
2. ODT claims covering excipient ratios, disintegration time and mechanical strength.
3. Liquid formulation claims covering pH, preservative concentration and stability.
4. Container-closure claims covering unit-dose or contamination-resistant delivery.
5. Manufacturing claims covering low-dose blend uniformity or sterile filling.
6. Use claims tied to a defined patient population, if supported by clinical evidence.

Patent value will depend on claim breadth, freedom-to-operate analysis, enablement, obviousness risk and the ability to detect infringement. A formulation patent based only on routine substitution of lactose, mannitol or magnesium stearate is unlikely to provide strong protection.

How does BENTYL compare with competing gastrointestinal antispasmodics?

Dicyclomine competes with other symptom-directed gastrointestinal products, including hyoscine butylbromide in markets where it is approved, peppermint-oil products and nonprescription agents such as simethicone or loperamide for different symptom profiles.

Product category	Primary commercial advantage	Excipient opportunity
Dicyclomine	Established antispasmodic use and multiple historical dosage forms	Liquid, ODT, lactose-free tablet and adherence packaging
Peppermint oil	Consumer familiarity and enteric-delivery positioning	Enteric coating, odor control and gastric protection
Simethicone	Broad OTC access and low-cost positioning	Chewable, suspension and combination formats
Loperamide	Diarrhea symptom control	Rapid-dissolve and chewable formats
Hyoscine butylbromide	Antispasmodic positioning in selected markets	Tablet, injection and fast-onset delivery

Dicyclomine's main weakness is anticholinergic tolerability. Its main formulation advantage is that a low-dose active can support compact tablets, liquids and rapidly disintegrating formats.

What is the revenue exposure and commercial outlook?

Because the active ingredient is generic, revenue depends on product differentiation and channel execution rather than molecule-level exclusivity. The highest potential value is likely to come from:

• Higher-margin specialty formulations.
• Institutional supply contracts.
• Reliable oral-solution availability.
• Private-label or contract-manufactured products.
• Regional markets with limited access to liquid or injectable antispasmodics.
• Packaging and administration systems that reduce medication errors.

A basic 10 mg capsule or 20 mg tablet is unlikely to sustain a large premium. An oral solution with validated taste acceptance, a calibrated delivery system and strong stability data has a better opportunity to defend pricing.

Key Takeaways

• BENTYL is dicyclomine hydrochloride, an old small-molecule antispasmodic with no biosimilar issue and limited remaining exclusivity value.
• Conventional tablets and capsules are low-risk but highly exposed to generic price competition.
• Oral liquids, ODTs, lactose-free tablets and unit-dose packaging offer the clearest excipient-led opportunities.
• Taste masking is the central technical challenge for liquid and orally disintegrating products.
• Preservative selection must be balanced against gastrointestinal tolerability, pH, microbial control and labeling.
• Sterile injectable products have higher manufacturing barriers but a narrower commercial market.
• Any defensible patent position should cover a specific formulation, delivery system or manufacturing process.
• The most attractive product concept is a palatable, accurately dosed oral liquid or ODT supported by a clear patient-use benefit.

FAQs

Can BENTYL be reformulated with sugar-free excipients?

Yes. Sorbitol, glycerin, maltitol, sucralose, acesulfame potassium and other systems may support a sugar-free oral liquid, but the formulation must control taste, osmolality, gastrointestinal tolerance and preservative performance.

Is an enteric-coated BENTYL tablet commercially attractive?

Usually not as a first-line strategy. Dicycline's antispasmodic action is intended for gastrointestinal smooth muscle, and delayed release could complicate onset and bioequivalence. An enteric-coated concept would require a strong pharmacokinetic or tolerability rationale.

Could a BENTYL product use an alcohol-free liquid vehicle?

Yes. An alcohol-free formulation can improve caregiver acceptance and broaden institutional use. The formulation would need alternative solubilization, preservation and flavor-control strategies.

Does BENTYL have pediatric formulation potential?

The label contraindicates use in infants younger than six months and identifies pediatric safety concerns. Pediatric development would require a defined target age group, dosing rationale, palatability work and regulatory support. [1]

What is the best first product for a pharmaceutical company entering the BENTYL market?

A differentiated oral liquid or ODT is more commercially defensible than another immediate-release tablet. The preferred concept would combine taste masking, accurate dosing, moisture-protective packaging and a regulatory pathway aligned with the intended product claims.

References

1. U.S. Food and Drug Administration. (2024). Bentyl (dicyclomine hydrochloride) prescribing information. FDA.
2. National Library of Medicine. (2024). DailyMed: Dicyclomine hydrochloride drug labels. U.S. National Library of Medicine.
3. United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary, General Chapter <51>: Antimicrobial effectiveness testing. USP.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.